At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 272 enrolled
Drug / intervention
LY3502970 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
In Brief
A Phase 2 clinical trial evaluating LY3502970 and Placebo for Obesity and Overweight and Obesity. Completed, enrolled 272 participants across 35 sites in 4 countries.
Detailed Summary
The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Overweight and Obesity
CountriesCanada, Hungary, Puerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedSep 2021
Enrollment StartSep 2021
Primary CompletionAug 2022
Study CompletionNov 2022
TodayJul 2026
First PostedSep 21, 2021
Enrollment StartSep 29, 2021
Primary CompletionAug 25, 2022
Study CompletionNov 22, 2022
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 4.8 years ago
Interventions
LY3502970drug
Administered orally
Placebodrug
Administered orally